GUR-701 is under clinical development by Gurus BioPharm and currently in Phase I for Androgenic Alopecia. According to GlobalData, Phase I drugs for Androgenic Alopecia does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GUR-701 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GUR-701 overview
GUR-701 is under development for the treatment of androgenetic alopecia. The drug candidate consists of three active pharmaceutical ingredients (API) they are Nitroproston (prostaglandin E2 and Nitric Oxide donor), Prostanit (prostaglandin E1 and Nitric Oxide donor) and Serinoprost (prostaglandin F2 and amino acid Serine). It is administered tropically and acts by targeting prostaglandins PGE1, PGE2 and PGF2. It is being developed based on Prostaglandin & Nitric Oxide research platform.
Gurus BioPharm overview
Gurus BioPharm is focused on the development of innovative drugs based on prostaglandins and nitric oxide to treat asthma, glaucoma and retina ischemia. Gurus BioPharm is headquartered in Claymont, Delaware, the US.
For a complete picture of GUR-701’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
